Incyte (INCY) Free Cash Flow Growth (5y) (2015 - 2026)
Incyte (INCY) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Incyte | 23.64 Bn | 19.62 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.40% |
| Dec 31, 2025 | 59.41% |
| Sep 30, 2025 | 32.42% |
| Jun 30, 2025 | -26.26% |
| Mar 31, 2025 | 18.91% |
| Dec 31, 2024 | 23.88% |
| Sep 30, 2024 | 1.42% |
| Jun 30, 2024 | -49.43% |
| Mar 31, 2024 | 9.72% |
| Dec 31, 2023 | 24.18% |
| Sep 30, 2023 | -6.88% |
| Jun 30, 2023 | 69.81% |
| Mar 31, 2023 | -72.27% |
| Dec 31, 2022 | 40.29% |
| Sep 30, 2022 | 25.88% |
| Jun 30, 2022 | 19.43% |
| Mar 31, 2022 | 25.34% |
| Dec 31, 2021 | 44.40% |
| Sep 30, 2021 | 8.00% |
| Jun 30, 2021 | 62.93% |